GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced plans to establish a major new global R&D center...
Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059)...
Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership
Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug...
Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial
Shionogi & Co., Ltd. (TYO: 4507) announced the U.S. commercial availability of XOCOVA (ensitrelvir), an...
Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma
Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company’s...
Humanwell Healthcare’s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials
Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial...
TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform
TPMeds announced the successful completion of an Angel financing round amounting to tens of millions...
AstraZeneca’s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data
AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet...
China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released a...
Changchun High-Tech Industries Subsidiary GenSci Advances Graves’ Disease Therapy to Phase II with US Partner Yarrow Bioscience
Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced that its subsidiary GenSci has initiated...
China’s NMPA Proposes Sweeping Reforms to Medical Device E-Commerce with New Draft Regulations
China’s National Medical Products Administration (NMPA) released the Administrative Measures for Medical Device Online Sales...
China’s 12th National Drug Procurement Round Attracts 500+ Companies, Targets 7.34 Billion Units
China’s National Drug Joint Procurement Office released enterprise-related information for the 12th batch of national...
HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
HBM Holdings Limited (HKG: 2142) announced a strategic cooperation framework agreement with China National Pharmaceutical...
Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
Antengene Corporation Limited (HKG: 6996) announced preliminary financial results for the six months ended June...
China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient...
Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
Broncus Medical Inc. (HKG: 2216) announced that its self-developed BroncTru disposable bronchoscopic dilation catheter has...
CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class...
Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its innovative antibody-drug conjugate...
CSPC’s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its...
Fosun Pharma’s DM1001 Receives NMPA Clearance for Parkinson’s Disease Clinical Trials
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical...